Verastem, Inc.
- VSTM
- NASDAQ
- Biotechnology
- Cancer Therapeutics (RAF/MEK Inhibitor)
- Oncology Drugs
$8.62
Today −0.35%Quote Oct 19, 2026, 08:00 PM UTC
+15.86%over the last month
Max drawdown −11.1%From 1-month high −6.6%3 months +43.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Verastem
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism.
Where the money comes from
Q2 2026 revenue $40.1M
- Government rebates and other incentives$6.1M15.3%
- Trade discounts and allowances$1.2M3.0%
- Returns$602,0001.5%
- Other / not reported$32.1M80.2%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
102
Founded
2010
Market value
$780.7M
Quote Oct 19
Floor
$8.59
0.3% below price
Resistance
$9.69
12.4% above price
Price vs analyst targets
19 analysts
Lowest target
$12.00Highest target
$22.00
$12.00Highest target
$22.00
- Price $8.62
- Average target $16.43
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 91% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about VSTMPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free